Logo image of EDIT

EDITAS MEDICINE INC (EDIT) Stock Overview

NASDAQ:EDIT - US28106W1036 - Common Stock

2.57 USD
-0.08 (-3.02%)
Last: 8/29/2025, 8:17:56 PM
2.57 USD
0 (0%)
After Hours: 8/29/2025, 8:17:56 PM

EDIT Key Statistics, Chart & Performance

Key Statistics
52 Week High4.12
52 Week Low0.91
Market Cap231.09M
Shares89.92M
Float89.64M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.85
PEN/A
Fwd PEN/A
Earnings (Next)11-03 2025-11-03/bmo
IPO02-03 2016-02-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


EDIT short term performance overview.The bars show the price performance of EDIT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

EDIT long term performance overview.The bars show the price performance of EDIT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EDIT is 2.57 USD. In the past month the price increased by 5.33%. In the past year, price decreased by -31.28%.

EDITAS MEDICINE INC / EDIT Daily stock chart

EDIT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About EDIT

Company Profile

EDIT logo image Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Company Info

EDITAS MEDICINE INC

11 Hurley St

Cambridge MASSACHUSETTS 02141 US

CEO: James C. Mullen

Employees: 246

EDIT Company Website

EDIT Investor Relations

Phone: 16174019000

EDITAS MEDICINE INC / EDIT FAQ

What is the stock price of EDITAS MEDICINE INC today?

The current stock price of EDIT is 2.57 USD. The price decreased by -3.02% in the last trading session.


What is the ticker symbol for EDITAS MEDICINE INC stock?

The exchange symbol of EDITAS MEDICINE INC is EDIT and it is listed on the Nasdaq exchange.


On which exchange is EDIT stock listed?

EDIT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EDITAS MEDICINE INC stock?

20 analysts have analysed EDIT and the average price target is 3.97 USD. This implies a price increase of 54.35% is expected in the next year compared to the current price of 2.57. Check the EDITAS MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EDITAS MEDICINE INC worth?

EDITAS MEDICINE INC (EDIT) has a market capitalization of 231.09M USD. This makes EDIT a Micro Cap stock.


How many employees does EDITAS MEDICINE INC have?

EDITAS MEDICINE INC (EDIT) currently has 246 employees.


What are the support and resistance levels for EDITAS MEDICINE INC (EDIT) stock?

EDITAS MEDICINE INC (EDIT) has a support level at 2.41 and a resistance level at 2.64. Check the full technical report for a detailed analysis of EDIT support and resistance levels.


Is EDITAS MEDICINE INC (EDIT) expected to grow?

The Revenue of EDITAS MEDICINE INC (EDIT) is expected to decline by -49.63% in the next year. Check the estimates tab for more information on the EDIT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EDITAS MEDICINE INC (EDIT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EDITAS MEDICINE INC (EDIT) stock pay dividends?

EDIT does not pay a dividend.


When does EDITAS MEDICINE INC (EDIT) report earnings?

EDITAS MEDICINE INC (EDIT) will report earnings on 2025-11-03, before the market open.


What is the Price/Earnings (PE) ratio of EDITAS MEDICINE INC (EDIT)?

EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.85).


What is the Short Interest ratio of EDITAS MEDICINE INC (EDIT) stock?

The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 8.76% of its float. Check the ownership tab for more information on the EDIT short interest.


EDIT Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT turns out to be only a medium performer in the overall market: it outperformed 63.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EDIT Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EDIT Financial Highlights

Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.85. The EPS decreased by -20.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -112.48%
ROE -1234.35%
Debt/Equity 2.69
Chartmill High Growth Momentum
EPS Q2Q%23.17%
Sales Q2Q%597.47%
EPS 1Y (TTM)-20.76%
Revenue 1Y (TTM)-41.97%

EDIT Forecast & Estimates

20 analysts have analysed EDIT and the average price target is 3.97 USD. This implies a price increase of 54.35% is expected in the next year compared to the current price of 2.57.

For the next year, analysts expect an EPS growth of 26.98% and a revenue growth -49.63% for EDIT


Analysts
Analysts72
Price Target3.97 (54.47%)
EPS Next Y26.98%
Revenue Next Year-49.63%

EDIT Ownership

Ownership
Inst Owners57.66%
Ins Owners0.24%
Short Float %8.76%
Short Ratio2.81